Ewing Sarcoma Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (09/21/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Ewing Sarcoma

Added Fluorine F 18-fludeoxyglucose (18F-FDG) uptake on positron emission tomography (PET) scan as a pretreatment prognostic factor for patients with Ewing sarcoma. Also added text to state that higher 18F-FDG uptake on PET scan correlates with a poorer outcome (cited Palmerini et al. as reference 32).

Treatment of Recurrent Ewing Sarcoma

Added text about the APEC1621 (NCT03155620) trial as a treatment option under clinical evaluation for recurrent Ewing sarcoma.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Late Effects of Treatment for Ewing Sarcoma

Next section >
About This PDQ Summary